InvestSMART

Prescient Therapeutics Limited (ASX:PTX)

ALERT: Price-sensitive ASX Announcement for PTX
Current share price for PTX : $0.068 -0.019 (-21.84%)+
Announcement
Release
27 Jul 2026 12:36PM
Price at Release
$0.087
Full Release
download
Summary
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, reported significant progress in its quarterly update for June 2026. The company has accelerated its PTX-100 Phase 2a clinical trial with 26 patients enrolled by the end of the quarter, and a further two patients enrolled post-quarter, aiming for a total of 40. Financially, Prescient closed the quarter with $9.03 million in cash, despite experiencing net operating cash outflows of $2.87 million due to substantial R&D investments. Key organizational developments include the appointment of Dr. Rosalind Wilson as Chief Medical Officer and active participation in international conferences for business development. The company's CellPryme and OmniCAR platforms continue to attract strategic interest, while its novel PTX-100 therapy, targeting the enzyme geranylgeranyl transferase-1, holds unique clinical potential as it progresses through regulatory approvals and international recruitment for clinical trials.
Key Points
  • Prescient ended the quarter with $9.03 million in cash.
  • Net operating cash outflows were $2.87 million, with $1.80 million on R&D.
  • PTX-100 Phase 2a trial has 28 enrollees, aiming for 40 total.
  • Dr. Rosalind Wilson appointed as Chief Medical Officer effective 13 July 2026.
  • Global clinical sites in Australia, U.S., Italy; expanding to France.
  • CEO attended major industry events in Europe and San Diego.
  • PTX-100 targets enzyme geranylgeranyl transferase-1, a novel approach.
  • Focus on business development for OmniCAR and CellPryme platforms.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.